Argenica Therapeutics Limited (ASX:AGN)
Australia · Delayed Price · Currency is AUD 0.2800
+0.0100 (3.70%)
Jan 30, 2026, 3:34 PM AEST
Argenica Therapeutics Revenue
In the fiscal year ending June 30, 2025, Argenica Therapeutics had annual revenue of 3.21M AUD with 23.70% growth. Argenica Therapeutics had revenue of 379.87K in the half year ending June 30, 2025, with 2.12% growth.
Revenue
3.21M
Revenue Growth
+23.70%
P/S Ratio
10.79
Revenue / Employee
n/a
Employees
n/a
Market Cap
34.68M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 3.21M | 615.81K | 23.70% |
| Jun 30, 2024 | 2.60M | 848.04K | 48.46% |
| Jun 30, 2023 | 1.75M | 1.49M | 575.38% |
| Jun 30, 2022 | 259.10K | -36.98K | -12.49% |
| Jun 30, 2021 | 296.08K | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Radiopharm Theranostics | 12.51M |
| Amplia Therapeutics | 5.01M |
| Prescient Therapeutics | 4.36M |
| Noxopharm | 2.82M |
| Tissue Repair | 2.63M |
| Neurotech International | 2.44M |
| Entropy Neurodynamics | 1.58M |
| Neurizon Therapeutics | 1.54M |